Soft Tissue Sarcoma Pipeline Grows as 70+ Pharma Companies Advance 75+ Novel Therapies, Finds DelveInsight | Philogen S.p.A., Chipscreen Biosciences, Lyvgen Biopharma

DelveInsight's "Soft Tissue Sarcoma - Pipeline Insight, 2026" report provides comprehensive insights about 70+ companies developing several pipeline drugs in the Soft Tissue Sarcoma (STS) pipeline landscape. It covers the STS pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Soft Tissue Sarcoma treatment landscape. Learn more about the evolving STS pipeline today @ https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Soft Tissue Sarcoma Pipeline Report

• Soft tissue sarcomas are rare malignant tumors originating in tissues like muscle, fat, and blood vessels.
• These tumors represent less than 1% of adult cancers but approximately 7% of childhood cancers.
• As of 2026, standard treatment involves surgery and radiation, though newer targeted therapies and immunotherapies are showing promise for high-grade or metastatic cases.
• DelveInsight's Soft Tissue Sarcoma Pipeline Insight report depicts a robust clinical development space with 70+ active players advancing 75+ pipeline therapies across multiple stages.
• Philogen S.p.A. holds one of the most clinically advanced STS pipeline candidates, Fibromun, currently in Phase III clinical evaluation.
• Chipscreen Biosciences is developing Chiauranib, a mid-stage selective inhibitor aimed at overcoming drug resistance through triple-pathway mechanisms.
• Lyvgen Biopharma's early-stage research includes LVGN6051, a monoclonal antibody designed to promote T-cell mediated anti-tumor immune responses.
• Leading STS companies include Philogen S.p.A., Chipscreen Biosciences, Lyvgen Biopharma, and others developing diverse therapeutic candidates.
• Promising therapies in development include Fibromun, Chiauranib, LVGN6051, and other clinical-stage candidates spanning monoclonal antibodies, small molecules, and gene therapies.

Download for updates and the latest revolution in STS care @ https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Soft Tissue Sarcoma Emerging Drugs Profile

• Fibromun: Philogen S.p.A.
Fibromun is a tumor-targeted immunomodulatory product independently developed by Philogen S.p.A.. As a late-stage therapy, it is currently undergoing evaluation in Phase III trials for the treatment of soft tissue sarcoma.

• Chiauranib: Chipscreen Biosciences
Chiauranib is a selective inhibitor developed by Chipscreen Biosciences designed to overcome drug resistance. It utilizes a triple-pathway mechanism of action and is currently in the mid-stage landscape of clinical development for STS.

• LVGN6051: Lyvgen Biopharma
LVGN6051 is a monoclonal antibody being researched by Lyvgen Biopharma in the early-stage landscape. It is designed to promote T-cell mediated anti-tumor immune responses to combat soft tissue sarcoma.

For more information on the Soft Tissue Sarcoma Emerging Drugs Profile, download DelveInsight's comprehensive Soft Tissue Sarcoma Pipeline Insight report @ https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Soft Tissue Sarcoma Pipeline Report Provides

• Detailed insights about companies developing therapies for Soft Tissue Sarcoma, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for STS treatment.
• STS companies that are involved in targeted therapeutics development with respective active and inactive projects.
• STS drugs under development based on stage of development, route of administration, and molecular type.
• Detailed analysis of collaborations, licensing agreements, and industry activities like mergers and acquisitions for future advancement of the STS market.

Learn more about Soft Tissue Sarcoma drug opportunities in our comprehensive STS pipeline report @ https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Soft Tissue Sarcoma Companies and Competitive Landscape

There are 70+ key companies, including Philogen S.p.A., Chipscreen Biosciences, Lyvgen Biopharma, and others, developing therapies for Soft Tissue Sarcoma, with more than 75 pipeline drugs across various stages of development.

DelveInsight's Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Soft Tissue Sarcoma products have been categorized under various Molecule types such as:

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Discover the latest advancements in Soft Tissue Sarcoma treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Soft Tissue Sarcoma Pipeline Report

• Coverage: Global
• Soft Tissue Sarcoma Companies: Philogen S.p.A., Chipscreen Biosciences, Lyvgen Biopharma, and others.
• Soft Tissue Sarcoma Therapies: Fibromun, Chiauranib, LVGN6051, and other pipeline candidates.
• Soft Tissue Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts, we offer customized research solutions to clients across the globe.

This release was published on openPR.